- Home
- TGTX vs SLNO Comparison
TGTX vs SLNO Comparison
Compare TGTX & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- SLNO
- Stock Information
- Founded
- TGTX 1993
- SLNO 1999
- Country
- TGTX United States
- SLNO United States
- Employees
- TGTX N/A
- SLNO N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- TGTX Health Care
- SLNO Health Care
- Exchange
- TGTX Nasdaq
- SLNO Nasdaq
- Market Cap
- TGTX 4.2B
- SLNO 3.8B
- IPO Year
- TGTX 1995
- SLNO 2014
- Fundamental
- Price
- TGTX $32.18
- SLNO $53.13
- Analyst Decision
- TGTX Strong Buy
- SLNO Strong Buy
- Analyst Count
- TGTX 4
- SLNO 10
- Target Price
- TGTX $42.50
- SLNO $112.50
- AVG Volume (30 Days)
- TGTX 2.0M
- SLNO 1.9M
- Earning Date
- TGTX 11-03-2025
- SLNO 11-05-2025
- Dividend Yield
- TGTX N/A
- SLNO N/A
- EPS Growth
- TGTX N/A
- SLNO N/A
- EPS
- TGTX 0.36
- SLNO N/A
- Revenue
- TGTX $454,069,000.00
- SLNO $32,656,999.00
- Revenue This Year
- TGTX $82.58
- SLNO N/A
- Revenue Next Year
- TGTX $44.99
- SLNO $175.39
- P/E Ratio
- TGTX $89.78
- SLNO N/A
- Revenue Growth
- TGTX 30.96
- SLNO N/A
- 52 Week Low
- TGTX $21.16
- SLNO $41.50
- 52 Week High
- TGTX $46.48
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- TGTX 57.80
- SLNO 24.74
- Support Level
- TGTX $31.34
- SLNO $50.63
- Resistance Level
- TGTX $32.57
- SLNO $72.99
- Average True Range (ATR)
- TGTX 1.13
- SLNO 4.27
- MACD
- TGTX 0.54
- SLNO -1.03
- Stochastic Oscillator
- TGTX 76.10
- SLNO 11.49
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.